WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 207118

CAS#: 197723-00-5

Description: NKP-1339, aslo known as IT-139 and KP-1339, is a ruthenium-based anticancer drug in clinical development against solid cancer with limited side effects. NKP-1339 shows promising results in solid tumors, such as non-small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 650 2 Weeks
10mg USD 950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23. Prices are subject to change without notice.

NKP-1339, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and SDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 207118
Name: NKP-1339
CAS#: 197723-00-5
Chemical Formula: C14H12Cl4N4NaRu
Exact Mass:
Molecular Weight: 502.1378
Elemental Analysis: C, 33.49; H, 2.41; Cl, 28.24; N, 11.16; Na, 4.58; Ru, 20.13

Synonym: NKP-1339; NKP 1339; NKP1339; IT-139; IT 139; IT139; KP-1339; KP 1339; KP1339; Na[trans-RuCl4(Ind)2; sodium trans-[RuCl4(HInd)2,

IUPAC/Chemical Name: Sodium hydride; tetrachloro-bis(1H-indazol-2-yl)ruthenium



SMILES Code: [Cl-][Ru+3]([N]1=CC2=CC=CC=C2N1)([Cl-])([Cl-])([N]3=CC4=CC=CC=C4N3)[Cl-].[Na+]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Alessio E, Messori L. NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules. 2019 May 24;24(10):1995. doi: 10.3390/molecules24101995. PMID: 31137659; PMCID: PMC6571951.

2: Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn PS, Buck A, Hofmann T, Gerner C, Hermann G, Koellensperger G, Keppler BK, Berger W, Heffeter P. Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Lett. 2017 Sep 28;404:79-88. doi: 10.1016/j.canlet.2017.07.009. Epub 2017 Jul 14. PMID: 28716523.

3: Bytzek AK, Koellensperger G, Keppler BK, G Hartinger C. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. J Inorg Biochem. 2016 Jul;160:250-5. doi: 10.1016/j.jinorgbio.2016.02.037. Epub 2016 Mar 3. PMID: 26993078.

4: Schreiber-Brynzak E, Klapproth E, Unger C, Lichtscheidl-Schultz I, Göschl S, Schweighofer S, Trondl R, Dolznig H, Jakupec MA, Keppler BK. Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Invest New Drugs. 2015 Aug;33(4):835-47. doi: 10.1007/s10637-015-0260-4. Epub 2015 Jun 21. PMID: 26091914.

5: Egger AE, Theiner S, Kornauth C, Heffeter P, Berger W, Keppler BK, Hartinger CG. Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. Metallomics. 2014 Sep;6(9):1616-25. doi: 10.1039/c4mt00072b. PMID: 24823867.

6: Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Körner W, Jungwirth U, Mohr T, Keppler BK, Berger W. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013 Oct;49(15):3366-75. doi: 10.1016/j.ejca.2013.05.018. Epub 2013 Jun 18. PMID: 23790465; PMCID: PMC3807657.

7: Dömötör O, Hartinger CG, Bytzek AK, Kiss T, Keppler BK, Enyedy EA. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. J Biol Inorg Chem. 2013 Jan;18(1):9-17. doi: 10.1007/s00775-012-0944-6. Epub 2012 Oct 18. PMID: 23076343.

8: Bytzek AK, Boeck K, Hermann G, Hann S, Keppler BK, Hartinger CG, Koellensperger G. LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma. Metallomics. 2011 Oct;3(10):1049-55. doi: 10.1039/c1mt00055a. Epub 2011 Sep 21. PMID: 21935553.

9: Hudej R, Turel I, Kanduser M, Scancar J, Kranjc S, Sersa G, Miklavcic D, Jakupec MA, Keppler BK, Cemazar M. The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. Anticancer Res. 2010 Jun;30(6):2055-63. PMID: 20651351.

10: Heffeter P, Böck K, Atil B, Reza Hoda MA, Körner W, Bartel C, Jungwirth U, Keppler BK, Micksche M, Berger W, Koellensperger G. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem. 2010 Jun;15(5):737-48. doi: 10.1007/s00775-010-0642-1. Epub 2010 Mar 11. PMID: 20221888; PMCID: PMC3371400.

11: Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G, Ziche M. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer. 2003 May 6;88(9):1484-91. doi: 10.1038/sj.bjc.6600906. PMID: 12778081; PMCID: PMC2741040.